跳至主要内容
临床试验/NCT01455961
NCT01455961已完成不适用

An Epidemiological Registry Study to Evaluate Clinical Practice Treatment in Patients With Bipolar Disorder Treated With Quetiapine XR and/or Quetiapine IR

AstraZeneca0 个研究点目标入组 16,000 人开始时间: 2011年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
16,000
主要终点
Description of detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before, at and after the index date.

研究概览

简要总结

The aim of this study is to describe the treatment pattern and patient characteristics in real life setting in patients with Bipolar disorder treated with Seroquel XR and/or Seroquel IR in Sweden.

详细描述

An epidemiological registry study to evaluate clinical practice treatment in patients with Bipolar Disorder treated with quetiapine XR and/or quetiapine IR

研究设计

研究类型
Observational
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients with a diagnosis of BD.

排除标准

  • Patients with a diagnosis of any schizophrenia spectrum disorder after the diagnosis of bipolar disorder.

结局指标

主要结局

Description of detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before, at and after the index date.

时间窗: 1st of January 2009 to 31st of December 2010.

次要结局

  • Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD and on treatment with quetiapine XR and/or quetiapine IR before and at the index date.(1st of January 2009 to 31st of December 2010.)
  • Description of the detailed clinical treatment in terms of duration of treatment, doses, drug switches, and add-on therapy, in patients with BD, including all drug treatment after the index date(1st of January 2009 to 31st of December 2010.)
  • Description of co-morbidity, demographics, sick leave, early retirement and socioeconomic factors in patients with BD, including all drug treatment before and at the index date(1st of January 2009 to 31st of December 2010.)

研究者

发起方
AstraZeneca
申办方类型
Industry
责任方
Sponsor

相似试验